natgillin/translations-raw huggingface dataset:
Figure 2 Kaplan-Meier plot of progression-free survival (investigator assessment, intentto-treat population) - PALOMA3 study
Slika 2. Kaplan-Meierova krivulja preživljenja bez progresije bolesti (ocjena ispitivača, populacija predviđena za liječenje) - ispitivanje PALOMA3
e Anaemia includes the following PTs: Anaemia, Haemoglobin decreased, Haematocrit decreased.
e Pojam 'anemija' obuhvaća sljedeće preporučene pojmove: anemiju, sniženu vrijednost hemoglobina, sniženu vrijednost hematokrita.
DOR (measurable disease) [months (95% CI)]
Trajanje odgovora (mjerljiva bolest) [mjeseci (95% CI)]
What Fulvestrant Mylan contains - The active substance is fulvestrant.
Što sadrži Fulvestrant Mylan - Djelatna tvar je fulvestrant.
Fulvestrant showed effects upon reproduction and embryo/foetal development consistent with its anti-estrogenic activity, at doses similar to the clinical dose.
Fulvestrant je, u dozama sličnima kliničkoj dozi, pokazao učinke na reprodukciju i razvoj embrija i fetusa sukladan svom antiestrogenskom djelovanju.
A Phase 3, international, randomised, double-blind, parallel-group, multicentre study of fulvestrant 500 mg plus palbociclib 125 mg versus fulvestrant 500 mg plus placebo was conducted in women with HR-positive, HER2-negative locally advanced breast cancer not amenable to resection or radiation therapy with curative intent or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after prior endocrine therapy in the (neo) adjuvant or metastatic setting.
Provedeno je međunarodno, randomizirano, dvostruko slijepo, multicentrično ispitivanje faze 3 s paralelnim skupinama, u kojem se kombinacija lijeka Faslodex u dozi od 500 mg i palbocikliba u dozi od 125 mg uspoređivala s kombinacijom lijeka Faslodex u dozi od 500 mg i placeba u žena - neovisno o njihovu menopauzalnom statusu - s lokalno uznapredovalim HR-pozitivnim i HER2-negativnim rakom dojke koji se nije mogao kurativno liječiti resekcijom ni radioterapijom ili metastatskim rakom dojke, kojima je bolest uznapredovala nakon prethodne endokrine terapije u (neo)adjuvantnim ili metastatskim uvjetima.
Two phase-3 clinical studies were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
Završena su dva klinička ispitivanja faze 3 s ukupno 851 ženom u postmenopauzi s uznapredovalim rakom dojke u kojih se bolest ponovno javila tijekom ili nakon adjuvantnog endokrinog liječenja ili je došlo do progresije nakon endokrinog liječenja uznapredovale bolesti.
Patients were well matched for baseline demographics and prognostic characteristics between the fulvestrant plus palbociclib arm and the fulvestrant plus placebo arm.
Početne demografske i prognostičke značajke bile su dobro ujednačene između skupine liječene lijekom Faslodex plus palbociklibom i one koja je primala Faslodex plus placebo.
A Phase 3, randomised, double-blind, double-dummy, multicentre study of fulvestrant 500 mg versus anastrozole 1 mg was conducted in postmenopausal women with ER-positive and/or PgR-positive locally advanced or metastatic breast cancer who had not previously been treated with any hormonal therapy.
Provedeno je randomizirano, dvostruko slijepo, multicentrično ispitivanje faze 3 s dvostrukim placebom u kojem se fulvestrant u dozi od 500 mg uspoređivao s anastrozolom u dozi od 1 mg u postmenopauzalnih žena s ER-pozitivnim i/ili PgR-pozitivnim lokalno uznapredovalim ili metastatskim rakom dojke koje prethodno nisu primile nikakvu hormonsku terapiju.
For user convenience, the needle bevel- up position is oriented to the lever arm (see Figure 4).
Radi lakše primjene kosi otvor vrha igle okrenut je prema ručici poluge (vidjeti Sliku 4).
• Administer intramuscularly slowly (1-2 minutes/injection) into the buttock (gluteal area).
• Primijenite sporom intramuskularnom injekcijom (12 minute po injekciji) u mišić stražnjice (područje gluteusa).
Fulvestrant + Palbociclib (N=345)
Faslodex + palbociklib (N=345)
Mylan Teoranta Coill Rua Inverin
Proizvođač MYLAN TEORANTA Inverin
In patients administered fulvestrant, an increase in exposure of this magnitude is expected to be well tolerated.
Očekuje se da će bolesnice koje su primile fulvestrant dobro podnijeti ovu razinu izloženosti.
Neoadjuvant treatment for up to 16 weeks in breast cancer patients treated with either fulvestrant 500 mg or fulvestrant 250 mg did not result in clinically significant changes in endometrial thickness, indicating a lack of agonist effect.
Neoadjuvantno liječenje tijekom najdulje 16 tjedana nije u bolesnica s rakom dojke liječenima fulvestrantom u dozi od 500 mg ili fulvestrantom u dozi od 250 mg dovelo do klinički značajnih promjena u debljini endometrija, što ukazuje da lijek nema agonistički učinak.
Fulvestrant plus palbociclib (N=206)
Faslodex plus palbociklib (N=206)
-AE subgroup (n=423) -AI subgroup (n=313)a a
- AE podskupina (n=423) - AI podskupina (n=313)a
Two clear type 1 glass pre-filled syringes with polypropylene plunger rod, fitted with a tamper-evident closure, each containing 5 ml Fulvestrant Mylan solution for injection.
Dvije napunjene štrcaljke od prozirnog stakla tipa 1 s potisnim klipom od polipropilena i sigurnosnim zatvaračem, od kojih svaka sadrži 5 ml Fulvestrant Mylan otopine za injekciju.
Very common Hypersensitivity reactionse Uncommon
Poremećaji imunološkog sustava vrlo često reakcije preosjetljivostie manje često anafilaktičke reakcije
A total of 521 pre/peri- and postmenopausal women who had progressed on or within 12 months from completion of adjuvant endocrine therapy on or within 1 month from prior endocrine therapy for advanced disease, were randomised 2:1 to fulvestrant plus palbociclib or fulvestrant plus placebo and stratified by documented sensitivity to prior hormonal therapy, menopausal status at study entry (pre/peri- versus postmenopausal), and presence of visceral metastases.
Ukupno je 521 žena u predmenopauzi/perimenopauzi i postmenopauzi kojoj je bolest progredirala tijekom ili unutar 12 mjeseci od završetka adjuvantne endokrine terapije odnosno tijekom ili unutar mjesec dana od završetka endokrine terapije za uznapredovalu bolest randomiziranu u omjeru 2:1 za liječenje kombinacijom lijeka Faslodex i palbocikliba ili kombinacijom lijeka Faslodex i placeba.
Adverse reactions listed below are classified according to frequency and System Organ Class (SOC).
Navedene nuspojave klasificirane su prema učestalosti i organskim sustavima.
How to use Fulvestrant Mylan
Kako primjenjivati Fulvestrant Mylan
Progression-Free Survival Number of PFS Events (%) PFS Hazard Ratio (95% CI) and pvalue
Preživljenje bez progresije bolesti Broj događaja PFS-a (%) Omjer hazarda (95% CI) i p-vrijednost za PFS
Fulvestrant plus palbociclib (N=141)
Faslodex plus palbociklib (N=141)
• Pull shield straight off needle to avoid damaging needle point.
• Povucite zaštitni zatvarač sa igle ravno kako ne biste oštetili vrh igle.
Mucosal inflammation, Oral pain, Oropharyngeal discomfort, Oropharyngeal pain, Stomatitis.
ulceracije u ustima, upalu sluznice, bol u usnoj šupljini, nelagodu u usnoj šupljini i ždrijelu, bol u usnoj šupljini i ždrijelu, stomatitis.
Nominal p-value with no adjustments made for multiplicity between the initial overall survival analyses at 50% maturity and the updated survival analyses at 75% maturity.
c Nominalna p-vrijednost bez korekcije za multiplicitet između inicijalnih analiza ukupnog preživljenja pri
Table 4 Summary of results of the primary efficacy endpoint (PFS) and key secondary efficacy endpoints (Investigator Assessment, Intent-To-Treat Population) ─ FALCON study
Tablica 4 Sažetak rezultata za primarnu mjeru ishoda za djelotvornost (PFS) i ključne sekundarne mjere ishoda za djelotvornost (ocjena ispitivača, populacija predviđena za liječenje)
Comparison between groups (Fulvestrant 500 mg/ Fulvestrant 250 mg) Hazard ratio
Usporedba između skupina (Fulvestrant 500 mg/Fulvestrant 250 mg) Apsolutna razlika u %
One clear type 1 glass pre-filled syringe with polypropylene plunger rod, fitted with a tamper-evident closure, containing 5 ml Fulvestrant Mylan solution for injection.
Jedne napunjene štrcaljke od prozirnog stakla tipa 1 s potisnim klipom od polipropilena i sigurnosnim zatvaračem, koja sadrži 5 ml Fulvestrant Mylan otopine za injekciju.
Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy have been reported with fulvestrant injection.
Kod primjene injekcije fulvestranta zabilježeni su događaji povezani s mjestom injiciranja uključujući išijas, neuralgiju, neuropatsku bol i perifernu neuropatiju.
Metabolism and nutrition disorders
Poremećaji metabolizma i prehrane često anoreksijaa
4.4 Special warnings and precautions for use Fulvestrant should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).
Fulvestrant treba primjenjivati uz oprez u bolesnica s blagim do umjerenim oštećenjem jetrene funkcije (vidjeti dijelove 4.2, 4.3 i 5.2).
Fulvestrant + placebo (N=172)
Faslodex + placebo (N=172)
Fulvestrant Mylan 250 mg solution for injection in prefilled syringe fulvestrant
Fulvestrant Mylan 250 mg otopina za injekciju u napunjenoj štrcaljki fulvestrant
Fulvestrant plus placebo (N=105)
Faslodex plus placebo (N=105)
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava često smanjen broj trombocitae
Fulvestrant plus placebo (N=69)
Faslodex plus placebo (N=69)
For the subgroup of patients with disease limited to non-visceral metastasis (n=208), the HR was 0.592 (95% CI: 0.419, 0.837) for the fulvestrant arm compared to the anastrozole arm. For the subgroup of patients with visceral metastasis (n=254), the HR was 0.993 (95% CI: 0.740, 1.331) for the fulvestrant arm compared to the anastrozole arm.
U podskupini bolesnica s bolešću ograničenom na nevisceralne metastaze (n=208) HR za skupinu liječenu fulvestrantom u odnosu na onu koja je primala anastrozol iznosio je 0,592 (95% CI: 0,419; 0,837).
Fulvestrant plus placebo (N=174)
Faslodex plus placebo (N=174)
All Patients -AE subgroup (n=423) -AI subgroup (n=313) a
Svi bolesnici - AE podskupina (n=423)
STATEMENT OF ACTIVE SUBSTANCE(S) One pre-filled syringe contains 250 mg fulvestrant in 5 ml solution
NAVOĐENJE DJELATNE(IH) TVARI Jedna napunjena štrcaljka sadržava 250 mg fulvestranta u 5 ml otopine.
Stomatitisg Diarrhoea Vomiting Skin and subcutaneous tissue disorders Very common Alopecia Rashh Common Dry skin General disorders and administration site conditions Very common Fatigue Pyrexia Common Asthenia Investigations Common AST increased ALT increased
Poremećaji probavnog sustava Vrlo često mučnina stomatitisg proljev povraćanje Poremećaji kože i potkožnog tkiva Vrlo često alopecija osiph Često suha koža Opći poremećaji i reakcije na mjestu primjene Vrlo često umor pireksija Često astenija Pretrage
Reproductive system and breast disorders Common
Klasifikacija organskih sustava Učestalost
When fulvestrant is combined with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.
Kada se fulvestrant kombinira s palbociklibom, vidjeti i sažetak opisa svojstava lijeka za palbociklib.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Fulvestrant Mylan 250 mg solution for injection in prefilled syringe fulvestrant
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Fulvestrant Mylan 250 mg otopina za injekciju u napunjenoj štrcaljki fulvestrant i.m. primjena
Adverse reactions by system organ class and frequency Infections and infestations
Infekcije i infestacije Vrlo često infekcijeb
When fulvestrant is used in combination with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.
Kada se fulvestrant primjenjuje u kombinaciji s palbociklibom, vidjeti i sažetak opisa svojstava lijeka za palbociklib.
f Thrombocytopenia includes the following PTs: Thrombocytopenia, Platelet count decreased.
f Pojam 'trombocitopenija' obuhvaća sljedeće preporučene pojmove: trombocitopeniju, snižen broj trombocita.
NAME OF THE MEDICINAL PRODUCT Fulvestrant Mylan 250 mg solution for injection in prefilled syringe
NAZIV LIJEKA Fulvestrant Mylan 250 mg otopina za injekciju u napunjenoj štrcaljki
You must not breast-feed while on treatment with Fulvestrant Mylan.
Tijekom liječenja lijekom Fulvestrant Mylan ne smijete dojiti.
What you need to know before you use Fulvestrant Mylan 3.
Što je Fulvestrant Mylan i za što se koristi Što morate znati prije nego počnete primjenjivati Fulvestrant Mylan Kako primjenjivati Fulvestrant Mylan Moguće nuspojave
OSb
CBR
PFS Median [months (95% CI)] Number of OS Events* OS Hazard Ratio (95% CI) and p-value
Broj događaja OS-a* Omjer hazarda (95% CI) i p-vrijednost za OS
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET B. UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET D. UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU
Combined analysis of both studies showed the hazard ratio of fulvestrant 250 mg to anastrozole for progression-free survival was
Kombinirana analiza obaju ispitivanja pokazala je da je omjer hazarda lijeka fulvestrant 250 mg u odnosu na anastrozol za preživljenje bez progresije bolesti bio 0,95 (95% CI 0,82 do 1,10).
Very common Elevated hepatic enzymes (ALT, AST, ALP) a
Često povišene vrijednosti AST-a povišene vrijednosti ALT-a
h Rash includes the following PTs: Rash, Rash maculo-papular, Rash pruritic, Rash erythematous, Rash papular,
h Pojam 'osip' obuhvaća sljedeće preporučene pojmove: osip, makulopapularni osip, pruritički osip, eritemski osip, papularni osip, dermatitis, akneiformni dermatitis, izbijanje kožnih promjena uzrokovanih toksičnim učinkom lijeka.
For the full list of all side effects reported with Copalia HCT, see the package leaflet.
For the full list of all side effects reported with Copalia HCT, see the pPackage lLeaflet.
The European Commission granted a marketing authorisation valid throughout the European Union for Copalia HCT on 4 November 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for Copalia HCT to Novartis Europharm Limited on 16 4 October November 2009.
The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Copalia HCT which combines the three substances in a single tablet.
The Committee for Medicinal Products for Human Use (CHMP) noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Copalia HCT which combines the three substances in a single tablet.
Copalia HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Copalia HCT.
Copalia HCT should must not be used in people who may beare hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Copalia HCT.
It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique).
anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique).
The CHMP therefore decided that Copalia HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
The Committeeand recommended that Copalia HCTit be given marketing authorisation.
This protein is often found on the surface of cells where it plays a role in regulating cell multiplication.
Taj se protein često nalazi na površini stanica gdje ima ulogu u regulaciji umnažanja stanica.
These three-week cycles should be repeated until the disease gets worse or side effects become unacceptable.
Te trotjedne cikluse treba ponavljati sve dok se bolest ne pogorša ili nuspojave ne postane nepodnošljive.
The recommended dose of Lartruvo is 15 mg per kilogram body weight, given twice over a period of three weeks, on days 1 and 8.
Preporučena doza lijeka Lartruvo je 15 mg po kilogramu tjelesne težine, a daje se dva puta u razdoblju od tri tjedna, svakog 1. i 8. dana.
What measures are being taken to ensure the safe and effective use of Lartruvo?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lartruvo?
The most serious side effects were neutropenia and musculoskeletal pain.
Najozbiljnije nuspojave bile su neutropenija i mišićnokoštana bol.
It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Objašnjava kako je Agencija ocijenila lijek kako bi preporučila njegovo odobrenje za stavljanje u promet u EU-u te uvjete za njegovu primjenu.
Doxorubicin is given on day 1 of each cycle, after the Lartruvo infusion.
Doksorubicin se daje 1. dana svakog ciklusa, nakon infuzije lijeka Lartruvo.
What is Lartruvo and what is it used for?
Što je Lartruvo i za što se koristi?
Lartruvo is available as a solution for infusion (drip) into a vein.
Lartruvo je dostupan kao otopina za infuziju (drip) u venu.
This is a summary of the European public assessment report (EPAR) for Lartruvo.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za Lartruvo.
During the infusion, patients should be monitored for signs and symptoms of infusion-related reactions and trained staff and equipment for emergency resuscitation should be available.
Tijekom infuzije bolesnike treba nadzirati zbog moguće pojave znakova i simptoma reakcija na infuziju, a na raspolaganju moraju biti osoblje i oprema za postupak oživljavanja.
By attaching to PDGFRα on sarcoma cells, Lartruvo is expected to block its activity, thereby slowing down the growth of the cancer.
Pričvršćivanjem za PDGFRα na stanicama sarkoma, očekuje se da će Lartruvo blokirati njegovu aktivnost i time usporiti rast stanica raka.
It is not intended to provide practical advice on how to use Lartruvo.
Svrha sažetka nije davati praktične savjete o primjeni lijeka Lartruvo.
Lartruvo has been given ‘conditional approval'.
Za lijek Lartruvo izdano je „uvjetno odobrenje”.
Why is Lartruvo approved?
Zašto je Lartruvo odobren?
Since Lartruvo has been granted a conditional approval, the company that markets Lartruvo will provide additional data from an ongoing study in order to further confirm the efficacy and safety of the medicine.
Budući da je lijek Lartruvo dobio uvjetno odobrenje, tvrtka koja stavlja na tržište lijek Lartruvo mora dostaviti dodatne podatke iz ispitivanja koja su u tijeku, kako bi se još više potvrdila djelotvornost i sigurnost ovoga lijeka.
Other information about Lartruvo
Ostale informacije o lijeku Lartruvo
The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Lartruvo's benefits are greater than its risks and recommended that it be approved for use in the EU.
Stoga je Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio da koristi od lijeka Lartruvo nadmašuju s njime povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
The summary of the opinion of the Committee for Orphan Medicinal Products for Lartruvo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Sažetak mišljenja Povjerenstva za lijekove za rijetke i teške bolesti o lijeku Lartruvo možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The most frequent side effects which lead to treatment termination were infusion-related reactions (allergic reactions which can be serious, with symptoms such as chills, fever and difficulty breathing) and mucositis.
Najčešće nuspojave koje dovode do prestanka liječenja bile su reakcije na infuziju (alergijske reakcije koje mogu biti ozbiljne, sa simptomima kao što su zimica, vrućica i otežano disanje) i mukozitis.
However, because of the small number of patients included in the main study, further data will be needed from the company that markets the medicine.
Međutim, kako je u glavno ispitivanje bio uključen mali broj ispitanika, potrebni su dodatni podaci tvrtke koja stavlja lijek na tržište.
In cancers such as soft tissue sarcoma, this protein is present in high levels or is overactive, causing cells to become cancerous.
Kod vrste raka kao što je sarkom mekog tkiva, taj je protein prisutan u velikim količinama ili je pretjerano aktivan, zbog čega stanice postaju kancerogene.
What are the risks associated with Lartruvo?
Koji su rizici povezani s lijekom Lartruvo?
The full EPAR for Lartruvo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Lartruvo nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Lartruvo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o liječenju lijekom Lartruvo pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lartruvo have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Lartruvo nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
Lartruvo can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the treatment of cancer.
Lartruvo se izdaje samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u primjeni terapija protiv raka.
The active substance in Lartruvo, olaratumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a protein called ‘platelet-derived growth factor receptor alpha' (PDGFRα).
Djelatna tvar lijeka Lartruvo, olaratumab, monoklonsko je protutijelo (vrsta proteina) koje prepoznaje i veže se za protein pod nazivom „alfa receptor za faktor rasta koji potječe od trombocita” (PDGFRα).
With regards to the safety profile of the medicine, it was observed that patients treated with Lartruvo plus doxorubicin experienced an increase in the frequency of side effects; however, in view of the benefits of treatment, side effects were considered tolerable and manageable.
S obzirom na sigurnosni profil lijeka, opaženo je da su bolesnici liječeni lijekom Lartruvo u kombinaciji s doksorubicinom imali veću učestalost nuspojava; ipak, u odnosu na koristi liječenja, nuspojave su se smatrale podnošljivima i moglo ih se kontrolirati.
Because the number of patients with soft tissue sarcoma is low, the disease is considered ‘rare', and Lartruvo was designated an ‘orphan medicine' (a medicine used in rare diseases) on 12 February 2015.
Budući da su bolesnici sa sarkomom mekog tkiva malobrojni, bolest se smatra „rijetkom” te je 12. veljače 2015.
In addition, patients treated with the combination Lartruvo plus doxorubicin lived overall almost twice as long as patients treated with doxorubicin (26.5 versus 14.7 months, respectively).
Osim toga, bolesnici liječeni kombinacijom lijeka Lartruvo i doksorubicina, živjeli su sveukupno gotovo dvostruko dulje nego bolesnici liječeni doksorubicinom (26,5 naspram 14,7 mjeseci).